Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GTB-5550 |
| Synonyms | |
| Therapy Description |
GTB-5550 is a tri-specific killer engager (TriKE) comprising nanobodies targeting CD16 and CD276 (B7H3) and wild-type IL15, which potentially induces antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 3435). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GTB-5550 | GTB5550|GTB 5550 | GTB-5550 is a tri-specific killer engager (TriKE) comprising nanobodies targeting CD16 and CD276 (B7H3) and wild-type IL15, which potentially induces antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 3435). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07541573 | Phase I | GTB-5550 | GTB-5550 in Advanced Solid Tumors | Recruiting | USA | 0 |